scholarly journals Differences in Outcomes of Chemoradiation in Women With Invasive Cervical Cancer by Human Immunodeficiency Virus Status: A Systematic Review

2021 ◽  
Vol 11 (1) ◽  
pp. 53-65
Author(s):  
Sidrah Shah ◽  
Melody Xu ◽  
Priyanka Mehta ◽  
Nicola M. Zetola ◽  
Surbhi Grover
Keyword(s):  
Systematic Review ◽  
Cervical Cancer ◽  
Human Immunodeficiency Virus ◽  
Invasive Cervical Cancer ◽  
Human Immunodeficiency Virus Status ◽  
Immunodeficiency Virus

scholarly journals LONG-TERM INCIDENCE OF CERVICAL CANCER IN WOMEN WITH HUMAN IMMUNODEFICIENCY VIRUS

2018 ◽  
Vol 8 (5-s) ◽  
pp. 394-399
Author(s):  
Subhash Kumar Mishra Golden ◽  
Nidhi Vishnoi
Keyword(s):  
Cervical Cancer ◽  
Human Immunodeficiency Virus ◽  
Cancer Prevention ◽  
Incidence Rate ◽  
Invasive Cervical Cancer ◽  
Incidence Rates ◽  
Self Report ◽  
Prevention Measures ◽  
Immunodeficiency Virus ◽  
Hiv Negative

Background: The objective of this study was to estimate the incidence of invasive cervical cancer (ICC) in women with human immunodeficiency virus (HIV) and compare it with the incidence in HIV-uninfected women. Methods: In a cohort study of HIV-infected and uninfected women who had Papanicolaou tests obtained every 6 months, pathology reports were retrieved for women who had biopsy results or a self report of ICC. Histology was reviewed when reports confirmed ICC. Incidence rates were calculated and compared with those in HIV-negative women. Results: After a median follow-up of 10.3 years, 3 ICCs were confirmed in HIV-seropositive women, and none were confirmed in HIV-seronegative women. The ICC incidence rate was not found to be associated significantly with HIV status (HIV-negative women [0 of 100,000 person-years] vs HIV-positive women [21.4 of 100,000 person-years]; P = .59). A calculated incidence rate ratio standardized to expected results from the Surveillance Epidemiology and End Results database that was restricted to HIV-infected Women’s Interagency HIV Study participants was 1.32 (95% confidence interval, 0.27-3.85; P = 0.80). Conclusions: Among women with HIV in a prospective study that incorporated cervical cancer prevention measures, the incidence of ICC was not significantly higher than that in a comparison group of HIV-negative women. Keywords: Cervical Cancer, Human Immunodeficiency Virus, Women, Cancer Prevention.

scholarly journals Residual or Recurrent Precancerous Lesions After Treatment of Cervical Lesions in Human Immunodeficiency Virus–infected Women: A Systematic Review and Meta-analysis of Treatment Failure

2019 ◽  
Vol 69 (9) ◽  
pp. 1555-1565 ◽  
Author(s):  
Pierre Debeaudrap ◽  
Joelle Sobngwi ◽  
Pierre-Marie Tebeu ◽  
Gary M Clifford
Keyword(s):  
Systematic Review ◽  
Cervical Cancer ◽  
Human Immunodeficiency Virus ◽  
Treatment Failure ◽  
Post Treatment ◽  
High Grade ◽  
Cervical Lesions ◽  
Pooled Prevalence ◽  
Increased Risk ◽  
Immunodeficiency Virus

Abstract Background Screening and treating premalignant cervical lesions (cervical intraepithelial neoplasia 2+ [CIN2+]) is an effective way to prevent cervical cancer, and recommendations exist for the monitoring of treatment success. Yet, there is no specific recommendation for human immunodeficiency virus (HIV)-infected women, who are at a known, increased risk of cervical cancer. Methods A systematic review was performed by searching MEDLINE, EMBASE, and Web of Science for studies published from January 1980 through May 2018. Eligible studies described the prevalence of histologically- and/or cytologically-defined lesions in HIV-infected women at least 6 months post-treatment. The primary endpoint was treatment failure, defined as the presence of residual and/or recurrent high-grade CIN2+/high-grade squamous intraepithelial lesions post-treatment. The pooled prevalence in HIV-infected women and the odds ratios (ORs) for HIV-infected compared to HIV-uninfected women were estimated using random-effects models. Results Among 40 eligible studies, the pooled prevalence of treatment failure in HIV-infected women was 21.4% (95% confidence interval [CI] 15.8–27.0). There was no significant difference in the treatment failure prevalence for cryotherapy (13.9%, 95% CI 6.1–21.6) versus loop electrosurgical excision procedure (13.8%, 95% CI 8.9–18.7; P = .9), but the treatment failure prevalence was significantly higher in women with positive (47.2%, 95% CI 22.0–74.0) than with negative (19.4%, 95% CI 11.8–30.2) excision margin (OR 3.4, 95% CI 1.5–7.7). Treatment failure was significantly increased in HIV-infected versus HIV-uninfected women, both overall (OR 2.7, 95% CI 2.0–3.5) and in all sub-group analyses. Conclusions There is strong evidence for an increased risk of treatment failure in HIV-infected women, in comparison to their HIV-negative counterparts. The only significant predictor of treatment failure in HIV-infected women was a positive margin status, but further data is needed on long-term outcomes after ablative treatment in HIV-infected women.

Reduction in prevalence of invasive cervical cancer in KwaZulu-Natal, South Africa: impact of the human immunodeficiency virus epidemic

2006 ◽  
Vol 16 (3) ◽  
pp. 1036-1040
Author(s):  
M. Moodley
Keyword(s):  
South Africa ◽  
Cervical Cancer ◽  
Human Immunodeficiency Virus ◽  
Hiv Infection ◽  
Invasive Cervical Cancer ◽  
Epidemiologic Data ◽  
Kwazulu Natal ◽  
Immunodeficiency Virus ◽  
Time Periods ◽  
Sub Saharan

The bulk of the human immunodeficiency virus (HIV) pandemic continues to ravage the developing world, especially sub-Saharan countries. The HIV seroprevalence among women with invasive cervical cancer varies in different parts of the world. A comparison of women with cervical cancer was undertaken for epidemiologic data in the province of KwaZulu-Natal, South Africa, which has the highest HIV prevalence. The two time periods of study were 1999 and 2003. The aim was to determine the trends of prevalence of invasive cervical cancer and HIV infection among such women. While the background prevalence of HIV infection among women with invasive cervical cancer in our setting has remained constant over the two time periods (21% and 21.8%), there has been a significant reduction in the number of women presenting with invasive cervical cancer to our center (672 to 271) over the two time periods, with no changes in other variables. On the contrary, the prevalence of HIV infection among antenatal attendees had risen from 32.5% to 38.5% in the 1999 and 2003 periods, respectively. Reasons for this dramatic trend are presented together with other epidemiologic data.

scholarly journals Human Immunodeficiency Virus and Human Papillomavirus Co-Infection in Pregnant Woman

2016 ◽  
Vol 16 (2) ◽  
pp. 26-27
Author(s):  
Anna Kornete ◽  
Elizabete Pumpure ◽  
Jana Zodzika ◽  
Dace Rezeberga ◽  
Liga Puksta-Gulbe ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Human Immunodeficiency Virus ◽  
Human Papillomavirus ◽  
Pregnant Woman ◽  
Vaginal Bleeding ◽  
Invasive Cervical Cancer ◽  
Hpv Infection ◽  
Condyloma Acuminata ◽  
Immunodeficiency Virus

Summary Among HIV-infected women prevalence and incidence of HPV infection are higher, and the risk for developing cervical cancer is increased. We present a case of HIV and HPV co-infection in woman with invasive cervical cancer and cervical and vaginal condyloma acuminata in association with vaginal bleeding during pregnancy.

scholarly journals Human immunodeficiency virus seroprevalence in patients with invasive cervical cancer in Zaria, North-Western Nigeria

2018 ◽  
Vol 17 (1) ◽  
pp. 17
Author(s):  
Adamu Abdullahi ◽  
MuhammadInuwa Mustapha ◽  
DawotolaAyorinde David ◽  
OlasindeTajudeen Ayodeji
Keyword(s):  
Cervical Cancer ◽  
Human Immunodeficiency Virus ◽  
Invasive Cervical Cancer ◽  
Immunodeficiency Virus ◽  
North Western
Sign in / Sign up

Export Citation Format

Share Document